Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRN101099 Food and PPI Effect Study in Healthy Adults
NCT07550946Phase 1Recruiting
- Sponsor
- Voronoi
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VRN101099 in solid tumor and cancer (2 arms), sponsored by Voronoi. Primary endpoints: Area under the plasma concentration-time curve from time 0 extrapolated to infinity, Concentration observed at 24 hours post-dose and 4 more. Started Jun 2026; status: recruiting.
02
Drugs
VRN101099
03
Conditions
solid tumorcancer
Beyond the preview
Go deeper on NCT07550946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550946.